StockNews.AI
OPTN
StockNews.AI
153 days

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

1. Optinose cancels earnings call scheduled for March 20, 2025. 2. Company to be acquired by Paratek Pharmaceuticals. 3. Acquisition subject to shareholder approval and customary conditions. 4. Optinose will report delayed results for 2024 promptly.

Earnings
+52.5%Current Return
VS
-0.29%S&P 500
$603/19 09:49 PM EDTEvent Start
$9.1503/21 04:09 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Very Bullish?

Acquisitions often lead to stock price increases. Past pharmaceutical acquisitions have shown price surges post-announcement.

How important is it?

The acquisition by Paratek enhances Optinose's market position and investor appeal, raising expectations.

Why Short Term?

Market reaction to acquisition news typically reflects in the short term. Historical acquisition announcements lead to immediate price adjustments.

Related Companies

PRTK
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner. About OptinoseOptinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn. Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com267.521.0531

Related News